Pathogenic Insights and Search for Biomarkers in RFC1-ataxia/CANVAS: a Model to a Deeper Understanding of Molecular Mechanisms Underlying Late-onset Neurodegeneration

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

CANVAS (Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome), also referred to as RFC1-ataxia, is a recently molecularly characterized neurodegenerative disorder caused by a biallelic expansion of an AAGGG pentanucleotide repeat in intron 2 of the Replication Factor C subunit 1 (RFC1) gene. This adult-onset condition presents with a variable combination of cerebellar ataxia, peripheral neuropathy, and vestibular dysfunction. Currently, limited data are available regarding its natural history and the molecular mechanisms by which this dynamic mutation leads to neurodegeneration of selective neuronal populations. Given that recent literature identifies RFC1/CANVAS as a relatively common genetic cause of late-onset ataxia, elucidation of its underlying pathogenic mechanisms may offer insights into the molecular pathways implicated in more prevalent late-onset neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: t
View:

• Molecular diagnosis of RFC1-ataxia

• age \>18 years and \<80 years

• ability to sign informed consent

Locations
Other Locations
Italy
Alma Mater Studiorum University of Bologna
ACTIVE_NOT_RECRUITING
Bologna
Department of Neuroscience
RECRUITING
Roma
Contact Information
Primary
Gabriella Silvestri
gabriella.silvestri@unicatt.it
+390630154435
Time Frame
Start Date: 2024-10-14
Estimated Completion Date: 2026-07-31
Participants
Target number of participants: 50
Treatments
Other: CANVAS patients
Patients with molecular diagnosis of RFC1-ataxia
Active_comparator: Healthy controls
Partners of patients with RFC1-ataxia
Sponsors
Leads: Catholic University of the Sacred Heart

This content was sourced from clinicaltrials.gov